AI Thinking Process
Kill Reason
Same-day cross-flavor buyer duplication: today's painpoint session (T5) already occupies the mid-tier biotech pharmacovigilance buyer slot. G194 cross-flavor same-day saturation kill rule fires. Alternative buyers (consumer rare-disease patient, US specialty-pharmacy insurer) both fail — ultra-rare patient consumer TAM is too small, and specialty-pharmacy insurers have adequate incumbent solutions from Oracle Argus, Aris Global, and IQVIA Safety Suite.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Consumer scale-shift on infrastructure tools has zero survival in eleven consecutive sessions. Consumer users do not care which underlying model their app uses — they want the app to work silently. Enterprise multi-model routing is already crowded (Portkey, OpenRouter, Helicone). A consumer-facing infrastructure transparency layer has no willingness to pay.
killed: LatAm consumer-navigator category is at confirmed saturation. Nubank's Nucrypto arm announced stablecoin plans in 2026. Rise.works and Bitso Business already address USDT payroll. B2B pivot lands on Deel's core territory. Market is closing from both the consumer end (Nubank/Nequi absorption) and the B2B end (Deel/Rise incumbency).
killed: Structural adoption barrier via lawyer-retainer channel. LatAm founders trust their lawyers as the authoritative source of regulatory intelligence; buying a third-party alert product signals distrust of their lawyer relationship. This structural barrier applies across markets (US Attorney IO variants, EU Lawgeex-founder arm) — not a LatAm-specific issue.